CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Statistics

Total Valuation

GDTC has a market cap or net worth of $23.08 million. The enterprise value is $21.22 million.

Market Cap	23.08M
Enterprise Value	21.22M

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GDTC has 11.54 million shares outstanding. The number of shares has increased by 8.56% in one year.

Current Share Class	11.54M
Shares Outstanding	11.54M
Shares Change (YoY)	+8.56%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	17.95%
Owned by Institutions (%)	0.43%
Float	3.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	-2,813.95
Forward PS	43.51
PB Ratio	4.19
P/TBV Ratio	4.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.81, with a Debt / Equity ratio of 0.07.

Current Ratio	5.81
Quick Ratio	5.81
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-204.67

Financial Efficiency

Return on equity (ROE) is -42.33% and return on invested capital (ROIC) is -29.10%.

Return on Equity (ROE)	-42.33%
Return on Assets (ROA)	-27.64%
Return on Invested Capital (ROIC)	-29.10%
Return on Capital Employed (ROCE)	-55.67%
Revenue Per Employee	n/a
Profits Per Employee	-$67,065
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.94% in the last 52 weeks. The beta is -0.37, so GDTC's price volatility has been lower than the market average.

Beta (5Y)	-0.37
52-Week Price Change	+29.94%
50-Day Moving Average	1.91
200-Day Moving Average	2.31
Relative Strength Index (RSI)	55.09
Average Volume (20 Days)	14,321

Short Selling Information

The latest short interest is 42,851, so 0.37% of the outstanding shares have been sold short.

Short Interest	42,851
Short Previous Month	33,520
Short % of Shares Out	0.37%
Short % of Float	1.19%
Short Ratio (days to cover)	3.29

Income Statement

In the last 12 months, GDTC had revenue of -$8,202 and -$2.88 million in losses. Loss per share was -$0.25.

Revenue	-8,202
Gross Profit	-47,216
Operating Income	-3.35M
Pretax Income	-2.89M
Net Income	-2.88M
EBITDA	-3.08M
EBIT	-3.35M
Loss Per Share	-$0.25

Balance Sheet

The company has $2.24 million in cash and $384,501 in debt, giving a net cash position of $1.86 million or $0.16 per share.

Cash & Cash Equivalents	2.24M
Total Debt	384,501
Net Cash	1.86M
Net Cash Per Share	$0.16
Equity (Book Value)	5.67M
Book Value Per Share	0.48
Working Capital	2.65M

Cash Flow

In the last 12 months, operating cash flow was -$2.48 million and capital expenditures -$658,035, giving a free cash flow of -$3.19 million.

Operating Cash Flow	-2.48M
Capital Expenditures	-658,035
Free Cash Flow	-3.19M
FCF Per Share	-$0.28

Margins

Gross Margin	n/a
Operating Margin	40,796.24%
Pretax Margin	35,227.31%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

GDTC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.56%
Shareholder Yield	-8.56%
Earnings Yield	-12.49%
FCF Yield	-13.82%

Analyst Forecast

The average price target for GDTC is $5.00, which is 150.00% higher than the current price. The consensus rating is "Buy".

Price Target	$5.00
Price Target Difference	150.00%
Analyst Consensus	Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3